Wolfe Research Maintains Outperform Rating on Eli Lilly Amid Strong Obesity Drug Data

Wolfe Research has reaffirmed its 'Outperform' rating for Eli Lilly (LLY) with a $1,350 price target. The firm cited strong Phase 3 data from retatrutide showing up to 26.1% weight reduction and improved cardiometabolic health indicators. Additionally, LLY acquired Engage Biologics in a deal valued at up to $202 million.

By Laiba Immad Thu, May 28, 2026 at 2:37 PM GMT+3 2 min read · Yahoo Finance · May 28, 2026, 11:37 UTC

Tickers: $LLY

Topics: Eli Lilly Engage Biologics acquisition GLP-1 therapies obesity pipeline Wolfe Research

Read the full article at Yahoo Finance

More World news

Allstate Announces Quarterly Dividend of $1.08 Per Share PR Newswire · November 12, 2026, 17:38 UTC
Stephanie Link Shifts AI Allocation from Nvidia to Micron Technology Following CEO Resignation CNBC · November 12, 2026, 17:37 UTC
Boyd Group Reports 28% Revenue Growth and $90 Million in Cost Savings for Q3 2026 Motley Fool · November 12, 2026, 17:33 UTC
Hugging Face CEO Reaffirms Commitment to Open-Source AI Following Nvidia CEO Jensen Huang's Departure TechCrunch · November 12, 2026, 17:36 UTC
Marimed Reports Record $44.2M Quarterly Revenue and Targets 2027 New York Launch Seeking Alpha · November 12, 2026, 17:30 UTC
Nebius Group Reports Massive Q3 2026 Revenue Growth Driven by AI Cloud Expansion Motley Fool · November 12, 2026, 17:29 UTC
Reagan Institute Launches Society of Fellows to Support Early Career Scholars PR Newswire · November 12, 2026, 17:32 UTC
Global Asset Management Group Signs LOI for $100 Million Affordable Housing Portfolio in Washington, D.C. PR Newswire · November 12, 2026, 17:30 UTC
U.S. Air Conditioner and Heat Pump Shipments Increase 27.3% in September Seeking Alpha · November 12, 2026, 17:27 UTC
Nvidia CEO Jensen Huang Resigns Amid Intelligence Probe Seeking Alpha · November 12, 2026, 17:27 UTC